% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Xia:284655,
      author       = {P. Xia and A. Dubrovska$^*$},
      title        = {{CD}98 heavy chain as a prognostic biomarker and target for
                      cancer treatment.},
      journal      = {Frontiers in oncology},
      volume       = {13},
      issn         = {2234-943X},
      address      = {Lausanne},
      publisher    = {Frontiers Media},
      reportid     = {DKFZ-2023-02056},
      pages        = {1251100},
      year         = {2023},
      abstract     = {The SLC3A2 gene encodes for a cell-surface transmembrane
                      protein CD98hc (4F2). CD98hc serves as a chaperone for LAT1
                      (SLC7A5), LAT2 (SLC7A8), y+LAT1 (SLC7A7), y+LAT2 (SLC7A6),
                      xCT (SLC7A11) and Asc1 (SLC7A10) providing their recruitment
                      to the plasma membrane. Together with the light subunits, it
                      constitutes heterodimeric transmembrane amino acid
                      transporters. CD98hc interacts with other surface molecules,
                      such as extracellular matrix metalloproteinase inducer CD147
                      (EMMPRIN) and adhesion receptors integrins, and regulates
                      glucose uptake. In this way, CD98hc connects the signaling
                      pathways sustaining cell proliferation and migration,
                      biosynthesis and antioxidant defense, energy production, and
                      stem cell properties. This multifaceted role makes CD98hc
                      one of the critical regulators of tumor growth, therapy
                      resistance, and metastases. Indeed, the high expression
                      levels of CD98hc were confirmed in various tumor tissues,
                      including head and neck squamous cell carcinoma,
                      glioblastoma, colon adenocarcinoma, pancreatic ductal
                      adenocarcinoma, and others. A high expression of CD98hc has
                      been linked to clinical prognosis and response to chemo- and
                      radiotherapy in several types of cancer. In this
                      mini-review, we discuss the physiological functions of
                      CD98hc, its role in regulating tumor stemness, metastases,
                      and therapy resistance, and the clinical significance of
                      CD98hc as a tumor marker and therapeutic target.},
      subtyp        = {Review Article},
      keywords     = {CD98hc (Other) / CSC: cancer stem cell (Other) / LAT1
                      (Other) / ferroptosis (Other) / therapy resistance (Other) /
                      tumor progression (Other) / xCT (Other)},
      cin          = {DD01},
      ddc          = {610},
      cid          = {I:(DE-He78)DD01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37823053},
      pmc          = {pmc:PMC10562705},
      doi          = {10.3389/fonc.2023.1251100},
      url          = {https://inrepo02.dkfz.de/record/284655},
}